The following is a sub-analysis of the local SOLVETM cohort in Turkey, the first observational study comparing the effects of once-daily insulin detemir with insulin glargine initiation as add-on therapy to OAD in patients with T2DM. This evidence concerns the gene INS and type 2 diabetes mellitus.